FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)
- PMID: 32994079
- DOI: 10.1016/j.jhep.2020.06.040
FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)
Keywords: FIB-4; Metabolic associated fatty liver disease; Nonalcoholic fatty liver disease.
Conflict of interest statement
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)".J Hepatol. 2021 Jan;74(1):248-249. doi: 10.1016/j.jhep.2020.09.007. Epub 2020 Sep 25. J Hepatol. 2021. PMID: 32981752 No abstract available.
-
Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?J Hepatol. 2021 Sep;75(3):725-726. doi: 10.1016/j.jhep.2021.05.035. Epub 2021 Jun 9. J Hepatol. 2021. PMID: 34116080 No abstract available.
Comment on
-
Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.J Hepatol. 2019 Aug;71(2):371-378. doi: 10.1016/j.jhep.2019.03.033. Epub 2019 Apr 6. J Hepatol. 2019. PMID: 30965069
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
